Horizon Pharma has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for Lodotra, for the treatment of rheumatoid arthritis.

Lodotra, which is currently approved for marketing in 16 European countries, is a modified (delayed)-release formulation of low-dose prednisone.

The NDA submission by the company is based on results from Circadian Administration of Prednisone in RA (CAPRA-2), a 12 week double-blind placebo-controlled Phase 3 trial involving 350 RA patients.

Results from CAPRA-2 demonstrated an improvement in American College of Rheumatology 20 (ACR20), ACR50 and ACR70 response criteria for patients who were treated with Lodotra compared to the placebo group.

In addition, data also included results from the 12 week double-blind placebo-controlled CAPRA-1 study evaluating 288 RA patients which showed a reduction in morning stiffness and IL-6 levels of approximately 29%.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.